Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.

MLA

Rossini, Daniele, et al. “Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 40, no. 25, Sept. 2022, pp. 2878–88. EBSCOhost, https://doi.org/10.1200/JCO.22.00839.

APA

Rossini, D., Antoniotti, C., Lonardi, S., Pietrantonio, F., Moretto, R., Antonuzzo, L., Boccaccino, A., Morano, F., Brugia, M., Pozzo, C., Marmorino, F., Bergamo, F., Tamburini, E., Passardi, A., Randon, G., Murgioni, S., Borelli, B., Buonadonna, A., Giordano, M., … Cremolini, C. (2022). Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 40(25), 2878–2888. https://doi.org/10.1200/JCO.22.00839

Chicago

Rossini, Daniele, Carlotta Antoniotti, Sara Lonardi, Filippo Pietrantonio, Roberto Moretto, Lorenzo Antonuzzo, Alessandra Boccaccino, et al. 2022. “Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 40 (25): 2878–88. doi:10.1200/JCO.22.00839.